The results revealed that patients with advanced or metastatic melanoma or NSCLC who subsequently received PD-1 antibody treatment presented similar tumour SUVmax values (SUVmax=4.9 and 6.5, respectively; P = 0.49). This evidence concerns the gene PDCD1 and neoplasm.